David Erritzoe
Academic clinical lecturer in psychiatry

What we (don’t) know about psychedelic microdosing

What is microdosing, why do people microdose, and what is the evidence for its effect? A new “self-blinding experiment” approach will be presented, and preliminary data from an Imperial College prospective online survey will be shown and discussed.

The “self-blinding experiment” is part of the Beckley/Imperial Research Programme.

David qualified as a medical doctor at Copenhagen University Medical School in 2001 and currently holds an Academic Clinical Lectureship in Psychiatry at Imperial College London. Alongside his clinical training in medicine/psychiatry, David has been involved in psychopharmacological research, using brain-imaging techniques such as PET and MRI. Initially working at Columbia University in New York, he then undertook a PhD at University Hospital Rigshospitalet in Copenhagen. Since 2009, under the mentorships of Profs Anne Lingford-Hughes and David Nutt at Imperial College London, he has conducted post-doc imaging research in the neurobiology of addictions and major depression. Together with Prof Nutt and Dr Carhart-Harris he is also investigating the neurobiology and therapeutic potential of MDMA and classic psychedelics.